Graves Induced Reversible LVOT Obstruction.

Athanasios Smyrlis, Dmitry Yaranov, Shahzad Khan, Marc Krichavsky, Lawrence Fisher

Abstract


Left ventricular outflow tract (LVOT) obstruction is most commonly associated with hypertrophic cardiomyopathy (HCM). Dynamic LVOT obstruction has been described in various clinical settings including Takotsubo cardiomyopathy, sepsis, treatment with adrenergic agonists and in the setting of acute anterior wall myocardial infarction. Reversible LVOT obstruction has been reported after treatment of pheochromocytoma. A common denominatorin these cases is increased inotropy of the basal LV segments, secondary to catecholamine excess, resulting in obliteration of the LVOT. We report the case of a 59 year old male with a structurally normal heart who developed symptomatic LVOT obstruction in the setting of Graves disease. His symptoms and LVOT gradient completely resolved once his thyroid function normalized with appropriate treatment. To our knowledge this is the first case report of hyperthyroidism induced reversible LVOT obstruction. 


References


Maron BJ, Bonow RO, Cannon RO 3rd, Leon MB, Epstein SE. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy. N Engl J Med. 1987 Apr 2;316(14):844-52. PMID:3547130

Auer J, Berent R, Weber T, Lamm G, Eber B. Catecholamine therapy inducing dynamic left ventricular outflow tract obstruction. Int J Cardiol. 2005 May 25;101(2):325-8. PMID:15882688

Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, SpencerCA, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994) National Health and Nutrition Examination Survey (NHANES III). J ClinEndocrinolMetab. 2002;87:489–99. PMID:11836274

Sawin CT, Castelli WP, Hershman JM, McNamara P, Bacharach P. The agingthyroid, Thyroid deficiency and the Framingham Study. Arch Intern Med.1985;145:1386–8. doi:10.1001/archinte.1985.00360080056006.

Kahaly GJ, Dillman WH. Thyroid hormone action in the heart. Endocr Rev.2005;26:704–28. PMID:15632316

Napoli R, Biondi B, Guardasole V, Matarazzo M, Pardo F, Angelini V, et al. Impact of hyperthyroidism and its correction on vascular reactivity in humans.Circulation. 2001;104:3076–80. doi: 10.1161/hc5001.100621

Biondi B, Palmieri EA, Lombardi G, Fazio S. Effects of thyroid hormone oncardiac function: the relative importance of heart rate, loading conditions, andmyocardial contractility in the regulation of cardiac performance in humanhyperthyroidism. J ClinEndocrinolMetab. 2002;87:968–74. PMID:11889145

Danzi S, Klein I. Thyroid hormone and blood pressure regulation. CurrHypertens Rep. 2003;5:513–20. PMID:14594573

Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J 2001 Feb 15;344(7):501-9. PMID:11172193

Osman F, Franklyn JA, Holder RL, Sheppard MC, Gammage MD. Cardiovascularmanifestations of hyperthyroidism before and after antithyroid therapy: amatched case-control study. J Am CollCardiol. 2007;49:71–81. PMID:17207725

Shewan LG, Coats AJS, Henein M. Requirements for ethical publishing in biomedical journals. International Cardiovascular Forum Journal 2015;2:2 DOI: 10.17987/icfj.v2i1.4




DOI: https://doi.org/10.17987/icfj.v8i0.166

Copyright (c) 2016 Athanasios Smyrlis

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.